Login to Your Account



Clinic Roundup


Monday, August 29, 2011
Emergent BioSolutions Inc., of Rockville, Md., said results from a Phase Ia trial of BioThrax, its anthrax vaccine adsorbed, with CPG 7909 adjuvant mixed at bedside generated peak antibody responses that were sixfold higher than those generated by BioThrax alone. The 69-subject study demonstrated that BioThrax plus CPG 7909 also accelerated the time to reach the peak immune response seen following BioThrax vaccination by three weeks.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription